| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ZIMV | Common Stock | Award | +1,676 | +346% | 2,160 | 01 Mar 2022 | Direct | F1, F2, F3 | ||
| transaction | ZIMV | Common Stock | Award | +2,164 | +100% | 4,324 | 01 Mar 2022 | Direct | F1, F3, F4 | ||
| transaction | ZIMV | Common Stock | Award | +4,215 | +97% | 8,539 | 01 Mar 2022 | Direct | F1, F3, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ZIMV | Stock Option (right to buy) | Award | +5,270 | 5,270 | 01 Mar 2022 | Common Stock | 5,270 | $20.49 | Direct | F1, F6, F7 | |||
| transaction | ZIMV | Stock Option (right to buy) | Award | +7,388 | 7,388 | 01 Mar 2022 | Common Stock | 7,388 | $24.01 | Direct | F1, F6, F8 | |||
| transaction | ZIMV | Stock Option (right to buy) | Award | +14,953 | 14,953 | 01 Mar 2022 | Common Stock | 14,953 | $23.56 | Direct | F1, F6, F9 | |||
| transaction | ZIMV | Stock Option (right to buy) | Award | +10,602 | 10,602 | 01 Mar 2022 | Common Stock | 10,602 | $22.54 | Direct | F1, F6, F10 | |||
| transaction | ZIMV | Stock Option (right to buy) | Award | +13,278 | 13,278 | 01 Mar 2022 | Common Stock | 13,278 | $24.37 | Direct | F1, F6, F11 | |||
| transaction | ZIMV | Stock Option (right to buy) | Award | +14,090 | 14,090 | 01 Mar 2022 | Common Stock | 14,090 | $31.03 | Direct | F1, F6, F12 | |||
| transaction | ZIMV | Stock Option (right to buy) | Award | +9,475 | 9,475 | 01 Mar 2022 | Common Stock | 9,475 | $32.26 | Direct | F1, F6, F13 |
| Id | Content |
|---|---|
| F1 | On March 1, 2022, Zimmer Biomet Holdings, Inc. ("Zimmer Biomet") completed a pro rata spinoff distribution (the "Distribution") of shares of ZimVie Inc. ("ZimVie") common stock, par value $ 0.01 per share ("ZimVie Common Stock") to the holders of record of Zimmer Biomet common stock, par value $ 0.01 per share ("Zimmer Biomet Common Stock") on February 15, 2022. In connection with the Distribution, pursuant to the terms of the Employee Matters Agreement, dated as of March 1, 2022, between Zimmer Biomet and ZimVie (the "EMA"), all outstanding equity awards with respect to Zimmer Biomet Common Stock held by the Reporting Person were equitably adjusted and converted into equity awards with respect to ZimVie Common Stock, with such equitable adjustments determined based on (i) the volume weighted average trading price of Zimmer Biomet Common Stock on February 28, 2022 and (ii) the volume weighted average trading price of ZimVie common stock on March 1 through March 3, 2022. |
| F2 | Represents the grant of restricted stock units with respect to ZimVie Common Stock ("ZimVie RSUs") upon the conversion of performance-based restricted stock units with respect to Zimmer Biomet Common Stock held by the Reporting Person as of March 1, 2022 in accordance with the terms of the EMA. The ZimVie RSUs vest on February 21, 2023. |
| F3 | Reflects 484 shares of ZimVie Common Stock received in the Distribution in respect of shares of Zimmer Biomet Common Stock held by the Reporting Person as of the record date for the Distribution. |
| F4 | Represents the grant of ZimVie RSUs upon the conversion of performance-based restricted stock units with respect to Zimmer Biomet Common Stock held by the Reporting Person as of March 1, 2022 in accordance with the terms of the EMA. The ZimVie RSUs vest on February 25, 2024. |
| F5 | Represents the grant of ZimVie RSUs upon the conversion of restricted stock units with respect to Zimmer Biomet Common Stock held by the Reporting Person as of March 1, 2022 in accordance with the terms of the EMA. The ZimVie RSUs vest on December 28, 2023. |
| F6 | Represents the grant of stock options to purchase ZimVie Common Stock upon the conversion of stock options to purchase Zimmer Biomet Common Stock in accordance with the terms of the EMA. |
| F7 | This option vests ratably in four annual installments on the first four anniversaries of the grant date, March 21, 2016. |
| F8 | This option vests ratably in four annual installments on the first four anniversaries of the grant date, March 21, 2017. |
| F9 | This option vests ratably in four annual installments on the first four anniversaries of the grant date, February 20, 2018. |
| F10 | This option vests ratably in four annual installments on the first four anniversaries of the grant date, March 20, 2018. |
| F11 | This option vests ratably in four annual installments on the first four anniversaries of the grant date, February 26, 2019. |
| F12 | This option vests ratably in four annual installments on the first four anniversaries of the grant date, February 21, 2020. |
| F13 | This option vests ratably in four annual installments on the first four anniversaries of the grant date, February 25, 2021. |
Senior Vice President, Chief Legal and Compliance Officer and Corporate Secretary